On 25 October, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the third quarter 2017.
Financial analysts and...Read more
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Norbert Oppitz has been appointed Senior Vice President for the newly established...Read more
Sobi Receives Approval from the FDA for Once-Daily Dosing Frequency of Orfadin® (nitisinone) for the Treatment of HT-1
First and only nitisinone product approved for once daily use in U.S., designed by Sobi to meet the changing needs of HT-1 patients entering older childhood, adolescence and adulthood.Read more
Sobi receives approval from the FDA for once-daily dosing frequency of Orfadin® for the treatment of HT-1
Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from the U.S. Food and Drug Administration (FDA) for a reduced dosing frequency for...Read more
As per 31 August 2017, the total number of shares in Swedish Orphan Biovitrum AB (publ) amounts to 272,507,708. All shares are common shares. The...Read more
Waltham, Mass., Aug. 16, 2017— Sobi, a leading integrated global biopharmaceutical company dedicated to rare and difficult-to-treat diseases,...Read more
The board of directors exercises authorization for repurchase of shares to secure the company’s commitments under incentive programme
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 4 May 2017 resolved – for the purpose of ensuring that the company can fulfil its...Read more
Sobi and Bioverativ highlight commitment to improving care for people with haemophilia at ISTH 2017 congressRead more
On 19 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2017.
Financial analysts and media...Read more